Reduced Frontal Glutamate + Glutamine and N-Acetylaspartate Levels in Patients With Chronic Schizophrenia but not in Those at Clinical High Risk for Psychosis or With First-Episode Schizophrenia
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Changes in brain pathology as schizophrenia progresses have been repeatedly suggested by previous studies. Meta-analyses of previous proton magnetic resonance spectroscopy ((1)H MRS) studies at each clinical stage of schizophrenia indicate that the abnormalities of N-acetylaspartate (NAA) and glutamatergic metabolites change progressively. However, to our knowledge, no single study has addressed the possible differences in (1)H MRS abnormalities in subjects at 3 different stages of disease, including those at ultrahigh risk for psychosis (UHR), with first-episode schizophrenia (FES), and with chronic schizophrenia (ChSz). In the current study, 24 patients with UHR, 19 FES, 25 ChSz, and their demographically matched 3 independent control groups (n = 26/19/28 for the UHR, FES, and ChSz control groups, respectively) underwent (1)H MRS in a 3-Tesla scanner to examine metabolites in medial prefrontal cortex. The analysis revealed significant decreases in the medial prefrontal NAA and glutamate + glutamine (Glx) levels, specifically in the ChSz group as indexed by a significant interaction between stage (UHR/FES/ChSz) and clinical status (patients/controls) (P = .008). Furthermore, the specificity of NAA and Glx reductions compared with the other metabolites in the patients with ChSz was also supported by a significant interaction between the clinical status and types of metabolites that only occurred at the ChSz stage (P = .001 for NAA, P = .004 for Glx). The present study demonstrates significant differences in (1)H MRS abnormalities at different stages of schizophrenia, which potentially correspond to changes in glutamatergic neurotransmission, plasticity, and/or excitotoxicity and regional neuronal integrity with relevance for the progression of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
The neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677
Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group
Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S. M., McFarlane, C. A., Hallgren, M., & McGorry, P. D. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00167-6 · Cited by 1,136
NMDA receptor subunits: function and pharmacology
PAOLETTI, P., & NEYTON, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.011 · Cited by 887
Cognitive Functioning in Prodromal Psychosis: A Meta-analysis
Fusar-Poli, P., Deste, G., Smieskova, R., Barlati, S., Yung, A. R., Howes, O., Stieglitz, R.-D., Vita, A., McGuire, P., & Borgwardt, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1592 · Cited by 691
MATSUOKA, K., UNO, M., KASAI, K., KOYAMA, K., & KIM, Y. (2006) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2006.01510.x · Cited by 491
Self-citationGlutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
Marsman, A., van den Heuvel, M. P., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr069 · Cited by 457
Walter, M., Henning, A., Grimm, S., Schulte, R. F., Beck, J., Dydak, U., Schnepf, B., Boeker, H., Boesiger, P., & Northoff, G. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.39 · Cited by 306
Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296
Research works printed but not linked: 67
- Jessen, 2006, Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia, Schizophr Res, 87, 81, 10.1016/j.schres.2006.06.011 · DOI
- Fusar-Poli, 2012, Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk, Arch Gen Psychiatry, 69, 220, 10.1001/archgenpsychiatry.2011.1472 · DOI · Paper page
- Koike, 2013, A multimodal approach to investigate biomarkers for psychosis in a clinical setting: the integrative neuroimaging studies in schizophrenia targeting for early intervention and prevention (IN-STEP) project, Schizophr Res, 143, 116, 10.1016/j.schres.2012.11.012 · DOI
- Smieskova, 2010, Neuroimaging predictors of transition to psychosis–a systematic review and meta-analysis, Neurosci Biobehav Rev, 34, 1207, 10.1016/j.neubiorev.2010.01.016 · DOI · Paper page
- Olabi, 2011, Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies, Biol Psychiatry, 70, 88, 10.1016/j.biopsych.2011.01.032 · DOI · Paper page
- Hirayasu, 1998, Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects, Am J Psychiatry, 155, 1384, 10.1176/ajp.155.10.1384 · DOI · Paper page
- Kasai, 2003, Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study, Arch Gen Psychiatry, 60, 766, 10.1001/archpsyc.60.8.766 · DOI · Paper page
- Pantelis, 2003, Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison, Lancet, 361, 281, 10.1016/S0140-6736(03)12323-9 · DOI · Paper page
- Suzuki, 2005, Differential contributions of prefrontal and temporolimbic pathology to mechanisms of psychosis, Brain, 128, 2109, 10.1093/brain/awh554 · DOI · Paper page
- Bates, 1996, Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo, Neuroreport, 7, 1397, 10.1097/00001756-199605310-00014 · DOI · Paper page
- Lentz, 2005, Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain, Radiology, 235, 461, 10.1148/radiol.2352040003 · DOI
- Stork, 2005, Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research, Mol Psychiatry, 10, 900, 10.1038/sj.mp.4001711 · DOI · Paper page
- Moffett, 2007, N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology, Prog Neurobiol, 81, 89, 10.1016/j.pneurobio.2006.12.003 · DOI · Paper page
- Magistretti, 1996, Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders, Ann N Y Acad Sci, 777, 380, 10.1111/j.1749-6632.1996.tb34449.x · DOI · Paper page
- Petroff, 2002, GABA and glutamate in the human brain, Neuroscientist, 8, 562, 10.1177/1073858402238515 · DOI · Paper page
- Krystal, 2008, Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia, Biol Psychiatry, 64, 358, 10.1016/j.biopsych.2008.06.011 · DOI
- Stone, 2010, Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis, Biol Psychiatry, 68, 599, 10.1016/j.biopsych.2010.05.034 · DOI
- Fusar-Poli, 2011, Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis, Arch Gen Psychiatry, 68, 881, 10.1001/archgenpsychiatry.2011.46 · DOI · Paper page
- Wood, 2007, Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T, Schizophr Res, 94, 328, 10.1016/j.schres.2007.05.008 · DOI
- Kraguljac, 2012, Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis, Psychiatry Res, 203, 111, 10.1016/j.pscychresns.2012.02.003 · DOI · Paper page
- De la Fuente-Sandoval, 2011, Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis, Neuropsychopharmacology, 36, 1781, 10.1038/npp.2011.65 · DOI · Paper page
- Bustillo, 2008, Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia, Neuropsychopharmacology, 33, 2456, 10.1038/sj.npp.1301631 · DOI
- Yang, 2008, Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4T, Magn Reson Med, 59, 236, 10.1002/mrm.21463 · DOI
- Jensen, 2009, Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla, NMR Biomed, 22, 762, 10.1002/nbm.1390 · DOI · Paper page
- Henry, 2011, Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a phantom study at 4 Tesla, J Magn Reson, 208, 210, 10.1016/j.jmr.2010.11.003 · DOI · Paper page
- First, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders, Non-patient Edition
- Iwashiro, 2012, Localized gray matter volume reductions in the pars triangularis of the inferior frontal gyrus in individuals at clinical high-risk for psychosis and first episode for schizophrenia, Schizophr Res, 137, 124, 10.1016/j.schres.2012.02.024 · DOI
- McGlashan, 2001, Structured Interview for Prodromal Syndromes (Version 3.0)
- Kay, 1987, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
- Barneveld, 2011, Overlap of autistic and schizotypal traits in adolescents with autism spectrum disorders, Schizophr Res, 126, 231, 10.1016/j.schres.2010.09.004 · DOI
- Aoki, 2012, Age-related change in brain metabolite abnormalities in autism: a meta-analysis of proton magnetic resonance spectroscopy studies, Transl Psychiatry, 2, e69, 10.1038/tp.2011.65 · DOI · Paper page
- Hollingshead, 1965, Two Factor Index of Social Position
- Oldfield, 1971, The assessment and analysis of handedness: the Edinburgh inventory, Neuropsychologia, 9, 97, 10.1016/0028-3932(71)90067-4 · DOI · Paper page
- Uetsuki, 2006, Estimation of premorbid IQ by JART in schizophrenia, Seishin Igaku, 48, 15
- Aoki, 2012, Absence of age-related prefrontal NAA change in adults with autism spectrum disorders, Transl Psychiatry, 2, e178, 10.1038/tp.2012.108 · DOI · Paper page
- Yamasue, 2002, 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia, Neuroreport, 13, 2133, 10.1097/00001756-200211150-00029 · DOI · Paper page
- Lutkenhoff, 2010, Proton MRS in twin pairs discordant for schizophrenia, Mol Psychiatry, 15, 308, 10.1038/mp.2008.87 · DOI
- Kraguljac, 2012, Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia, Neuropsychopharmacology, 37, 2635, 10.1038/npp.2012.126 · DOI · Paper page
- Reid, 2010, Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia, Biol Psychiatry, 68, 625, 10.1016/j.biopsych.2010.04.013 · DOI · Paper page
- Waddell, 2011, Anterior cingulate and cerebellar GABA and Glu correlations measured by ¹H J-difference spectroscopy, Magn Reson Imaging, 29, 19, 10.1016/j.mri.2010.07.005 · DOI · Paper page
- Tal, 2012, The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging, NMR Biomed, 25, 1392, 10.1002/nbm.2812 · DOI
- O’Neill, 2004, 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia, Neuroimage, 21, 1781, 10.1016/j.neuroimage.2003.11.005 · DOI
- Bartha, 1997, Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy, Arch Gen Psychiatry, 54, 959, 10.1001/archpsyc.1997.01830220085012 · DOI · Paper page
- Théberge, 2002, Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers, Am J Psychiatry, 159, 1944, 10.1176/appi.ajp.159.11.1944 · DOI · Paper page
- Bertolino, 2003, Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder, Am J Psychiatry, 160, 483, 10.1176/appi.ajp.160.3.483 · DOI · Paper page
- Fannon, 2003, Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia, Biol Psychiatry, 54, 587, 10.1016/S0006-3223(03)00185-9 · DOI
- Yasukawa, 2005, Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert’s syndrome), J Psychiatry Neurosci, 30, 416
- Ohrmann, 2008, Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy, Schizophr Res, 106, 156, 10.1016/j.schres.2008.08.005 · DOI
- Thomas, 1998, Preliminary study of frontal lobe 1H MR spectroscopy in childhood-onset schizophrenia, J Magn Reson Imaging, 8, 841, 10.1002/jmri.1880080413 · DOI · Paper page
- Egerton, 2012, Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia, Neuropsychopharmacology, 37, 2515, 10.1038/npp.2012.113 · DOI · Paper page
- Velakoulis, 2002, Increased duration of illness is associated with reduced volume in right medial temporal/anterior cingulate grey matter in patients with chronic schizophrenia, Schizophr Res, 57, 43, 10.1016/S0920-9964(01)00307-3 · DOI
- Premkumar, 2008, Association between a longer duration of illness, age and lower frontal lobe grey matter volume in schizophrenia, Behav Brain Res, 193, 132, 10.1016/j.bbr.2008.05.012 · DOI
- McCarley, 1996, Neuroimaging and the cognitive neuroscience of schizophrenia, Schizophr Bull, 22, 703, 10.1093/schbul/22.4.703 · DOI · Paper page
- Clark, 2006, N-acetylaspartate as a reservoir for glutamate, Med Hypotheses, 67, 506, 10.1016/j.mehy.2006.02.047 · DOI
- Meyer-Lindenberg, 2011, Neuroimaging and the question of neurodegeneration in schizophrenia, Prog Neurobiol, 95, 514, 10.1016/j.pneurobio.2011.07.007 · DOI
- Kim, 2005, A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders–focus on magnetic resonance spectroscopy (MRS) studies, Hum Psychopharmacol, 20, 309, 10.1002/hup.693 · DOI · Paper page
- Yoo, 2009, Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus, Schizophr Res, 111, 86, 10.1016/j.schres.2009.03.036 · DOI
- Sijens, 1995, 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study, Magn Reson Med, 33, 818, 10.1002/mrm.1910330612 · doi:10.1002/mrm.1910330612
- Moore, 2002, Mesial temporal lobe Cho to Cr(PCr) ratio asymmetry in chronic schizophrenics, Schizophr Res, 57, 35, 10.1016/S0920-9964(01)00302-4 · DOI
- Szulc, 2005, The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS), Pharmacopsychiatry, 38, 214, 10.1055/s-2005-873156 · DOI · Paper page
- Szulc, 2011, Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment, Pharmacopsychiatry, 44, 148, 10.1055/s-0031-1279739 · DOI · Paper page
- Goto, 2012, Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia, Neuropsychiatr Dis Treat, 8, 119
- Qayyum, 2009, MR spectroscopy of the liver: principles and clinical applications, Radiographics, 29, 1653, 10.1148/rg.296095520 · DOI
- Wijtenburg, 2011, Very short echo time improves the precision of glutamate detection at 3T in 1H magnetic resonance spectroscopy, J Magn Reson Imaging, 34, 645, 10.1002/jmri.22638 · DOI
- Mullins, 2008, Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites, Magn Reson Med, 60, 964, 10.1002/mrm.21696 · DOI
- Seeger, 2003, Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases, Magn Reson Med, 49, 19, 10.1002/mrm.10332 · DOI · Paper page
- Auer, 2001, Improved analysis of 1H-MR spectra in the presence of mobile lipids, Magn Reson Med, 46, 615, 10.1002/mrm.1235 · doi:10.1002/mrm.1235
Cited by
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
“…schizophrenia have generally found normal or reduced cortical glutamate and glutamine levels (Block et al., 2000; Kegeles et al., 2000b; Lutkenhoff et al., 2010; Natsubori et al., 2014; Ohrmann et al., 2005; Ongur et al., 2009; Rowland et al., 2009; Tayoshi et al., 2009; Théberge et al., 2003).”
BackgroundMerritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Optimizing the use of biologgers for movement ecology research
Williams, H. J., Taylor, L. A., Benhamou, S., Bijleveld, A. I., Clay, T. A., de Grissac, S., Demšar, U., English, H. M., Franconi, N., Gómez‐Laich, A., et al. (2020) · Journal of Animal Ecology · doi:10.1111/1365-2656.13094 · Cited by 333
Foss-Feig, J. H., Adkinson, B. D., Ji, J. L., Yang, G., Srihari, V. H., McPartland, J. C., Krystal, J. H., Murray, J. D., & Anticevic, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.005 · Cited by 310
The neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Metadata
- Authors
- Natsubori, T., Inoue, H., Abe, O., Takano, Y., Iwashiro, N., Aoki, Y., Koike, S., Yahata, N., Katsura, M., Gonoi, W., Sasaki, H., Takao, H., Kasai, K., & Yamasue, H.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-10
- Volume
- 40
- Issue
- 5
- Pages
- 1128-1139
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2099703108
- Cited by
- 99
- References
- 18
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Frontal Glutamate + Glutamine and N-Acetylaspartate Levels in Patients With Chronic Schizophrenia but not in Those at Clinical High Risk for Psychosis or With First-Episode Schizophrenia. https://app.cochat.ai/papers/10.1093/schbul/sbt124
- The paper
- Natsubori, T., Inoue, H., Abe, O., Takano, Y., Iwashiro, N., Aoki, Y., Koike, S., Yahata, N., Katsura, M., Gonoi, W., Sasaki, H., Takao, H., Kasai, K., & Yamasue, H. (2014). Reduced Frontal Glutamate + Glutamine and N-Acetylaspartate Levels in Patients With Chronic Schizophrenia but not in Those at Clinical High Risk for Psychosis or With First-Episode Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbt124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.